Skip to main content

Table 5 Treatment response of chronic ITP patients with IFN-γ and IFN-γR

From: The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP

 

IFN-γ AA

IFN-γ non-AA

 

IFN-γR　AA

IFN-γR　non-AA

 

N

(%)

N

(%)

P value

OR

95% CI

N

(%)

N

(%)

P value

OR

95%

All treatment, no. of cases (%)

82

(75.9)

15

(83.3)

0.76

0.66

0.18–2.48

89

(77.4)

8

(72.7)

0.71

1.35

0.33–5.47

 Second line treatment, no. of cases (%)

33

(30.6)

4

(22.2)

0.58

1.54

0.47–5.03

33

(28.7)

4

(36.4)

0.73

0.70

0.19–2.57

Second line treatment, no. of cases (%)

 CR, no. of cases (%)

57

(69.5)

11

(73.3)

1.00

0.83

0.24–2.86

64

(71.9)

4

(50.0)

0.23

2.56

0.59–11.03

 RR (CR+R), no. of cases (%)

79

(96.3)

13

(86.7)

0.17

4.05

0.62–26.62

85

(95.5)

7

(87.5)

0.36

3.04

0.30–30.98

Prednisolone therapy, no. of cases (%)

68

(63.0)

14

(77.8)

0.29

0.49

0.15–1.58

76

(66.1)

6

(54.5)

0.51

1.62

0.47–5.66

Response to prednisolone therapy

 CR, no. of cases (%)

37

(54.4)

8

(57.1)

1.00

0.90

0.28–2.86

42

(55.3)

3

(50.0)

1.00

1.24

0.23–6.52

 RR (CR+R), no. of cases (%)

63

(92.6)

11

(78.6)

0.13

3.44

0.72–16.49

68

(89.5)

6

(100)

1.00

  

Splenectomy, no. of cases (%)

17

(15.7)

2

(11.1)

1.00

1.50

0.32–7.10

18

(15.7)

1

(9.1)

1.00

1.86

0.22–15.40

Response to splenectomy

 CR, no. of cases (%)

10

(58.8)

1

(50.0)

1.00

1.43

0.08–26.90

11

(61.1)

0

(0)

0.42

  

 RR (CR+R), no. of cases (%)

13

(76.5)

1

(50.0)

0.47

3.25

0.16–64.61

14

(77.8)

0

(0)

0.26

  

Eradication of Helicobacter pylori, no. of cases (%)

40

(37.0)

3

(16.7)

0.11

3.03

0.83–11.12

38

(33.0)

5

(45.5)

0.51

0.61

0.17–2.12

Response to eradication of Helicobacter pylori

 CR, no. of cases (%)

19

(47.5)

1

(33.3)

1.00

1.81

0.15–21.59

17

(44.7)

3

(60.0)

0.65

0.54

0.08–3.61

Severe ITP, no. of cases (%)

23

(21.3)

1

(5.6)

0.19

4.60

0.58–36.41

22

(19.1)

2

(18.2)

1.00

1.07

0.22–5.28

Refractory ITP, no. of cases (%)

9

(8.3)

1

(5.6)

1.00

1.55

0.18–12.99

9

(7.8)

1

(9.1)

1.00

0.85

0.10–7.40

Corticosteroid-dependent, no. of cases (%)

30

(28.8)

7

(41.2)

0.40

0.58

0.20–1.66

35

(30.4)

2

(18.2)

0.72

1.84

0.37–9.13

  1. Second line treatment: Patients in need of second line, CR (complete response): platelet count of at least 100 × 109/L, R (response): platelet count between 30 and 100 × 109/L and at least double the baseline count, severe ITP: presence of bleeding symptoms at presentation sufficient to mandate treatment, or occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose, refractory ITP: failure to achieve at least R or loss of R after splenectomy, loss of R: platelet count 30 × 109/L or a less than 2-fold increase in platelet count from baseline or the presence of bleeding, corticosteroid-dependence: the ongoing need for continuous corticosteroid administration or frequent courses of corticosteroids to maintain a platelet count at or above 30 × 109/L and/or to avoid bleeding.
  2. ITP immune thrombocytopenia, IFN interferon, IL interleukin, OR odds ratio, CI confidence interval, SD standard deviation
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us